A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

This is a phase I study to evaluate the safety and preliminary efficacy of [225Ac]Ac-DOTATATE injection combined with tislelizumab in the maintenance treatment period for patients of extensive-stage small cell lung cancer (ES-SCLC) with somatostatin receptors (SSTR)+ as first-line treatment.Patients with ES-SCLC who have completed the induction therapy of first-line standard treatment and are yet to enter the maintenance treatment period are planned to be enrolled.

开始日期2026-01-20

申办/合作机构

北京肿瘤医院（北京大学肿瘤医院）

NCT07150806

/ Recruiting临床1/2期IIT

Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.

开始日期2025-11-12

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

NCT06411301

/ Withdrawn临床1期IIT

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received at least 3 prior lines of myeloma therapy. Participants will be selected based on somatostatin receptor (SSTR) positivity assessed by gallium-68 labelled DOTA-octreotate (68Ga-DOTATATE) PET/CT. The response to 225Ac-DOTATATE therapy will also be assessed in the target study population.

开始日期2024-10-01

申办/合作机构

Jules Bordet Institute

[+1]

100 项与锕[225Ac]氧奥曲肽相关的临床结果

登录后查看更多信息

100 项与锕[225Ac]氧奥曲肽相关的转化医学

登录后查看更多信息

100 项与锕[225Ac]氧奥曲肽相关的专利（医药）

登录后查看更多信息

项与锕[225Ac]氧奥曲肽相关的文献（医药）

2026-10-01·CLINICAL NUCLEAR MEDICINE

Targeted Alpha Therapy With [225Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT With [177Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [177Lu]Lu-DOTATATE Treatment

Article

作者: Agrawal, Roopal ; Parghane, Rahul V. ; Basu, Sandip

Objectives::

To evaluate and compare the therapeutic response, progression-free survival (PFS), overall survival (OS), and clinical toxicity of targeted alpha therapy (TAT) [ 225 Ac]Ac-DOTATATE and salvage [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumor (NET) patients who showed an objective response or disease stabilization following an initial course of [ 177 Lu]Lu-DOTATATE PRRT and eventually developed progressive disease after a time interval of more than 6 months.

Patients and Methods::

This was a single-institution, retrospective observational analysis conducted at a tertiary care institute. The medical records of metastatic NET patients who had been previously treated with an initial course of PRRT (I-PRRT) with 4–6 cycles of [ 177 Lu]Lu-DOTATATE and showed an objective response or stable disease (SD) on the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria after I-PRRT, but eventually developed progressive disease (PD) after a time gap of more than 6 months, and subsequently received [ 225 Ac]Ac-DOTATATE or salvage [ 177 Lu]Lu-DOTATATE were analyzed. These patients with matched baseline characteristics (site of primary disease, WHO grading of tumors, Ki-67 index, disease burden, [ 18 F]F-FDG avidity, and previously treatments) were divided into the 2 treatment arms based on the treatment received by them, which in turn depended upon availability of therapeutic radionuclide, patient choice, and financial constraints as follows: Arm A: [ 225 Ac]Ac-DOTATATE and Arm B: salvage [ 177 Lu]Lu-DOTATATE. The treatment response was evaluated under 3 categories for all patients: (a) symptomatic, (b) biochemical, and (c) functional and anatomic imaging response.

Results::

A total of 40 patients with metastatic NET (20 in each arm) were included and analyzed in the study. On the symptomatic response, 3 (15%) patients demonstrated a complete response (CR), and 7 (35%) patients demonstrated partial response (PR) in arm A, compared with no CR and PR of 4 (20%) patients in arm B. Biochemical response assessed by using serum CgA showed partial improvement in 10 (50%) patients in arm A versus 5 (25%) patients in arm B. On anatomic imaging, the disease control rate (DCR) was found to be 80% in arm A and 60% in arm B. The objective response rate (ORR) calculated based upon RECIST 1.1 criteria was 35% in arm A and 10% in arm B. The median progression-free survival was 10 months (95% CI, 6.0–24.0) in arm A and 12 months (95% CI, 4.0–33.0) in arm B, while the median overall survival was 16 months (95% CI, 10–16) in arm A and was not reached in arm B; neither difference reached statistical significance. Toxicities in both arms were predominantly mild and manageable, with no grade 3 or higher adverse events in either arm.

Conclusions::

This observational study shows that [ 225 Ac]Ac-DOTATATE and salvage PRRT with [ 177 Lu]Lu-DOTATATE are both efficacious and well-tolerated treatments for progressive metastatic NETs without high-grade toxicity. The numerically superior clinical, biochemical, and imaging response rates observed with TAT indicate that alpha-emitting radionuclides may partly overcome resistance to prior beta-emitter therapy. Prospective, larger multicenter randomized trials are needed to validate these findings, refine patient selection, and determine the appropriate treatment of alpha- or salvage beta-emitting radionuclide therapies in progressive NETs.

2026-08-01·JOURNAL OF NUCLEAR MEDICINE

Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [ ²²⁵ Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor–Expressing, Well-Differentiated GEP-NETs

Article

作者: Ulaner, Gary A ; Frey, Eric ; Sgouros, George ; Morris, Michael ; Scott, Aaron ; Ferreira, Denis ; Sneeden, Eileen ; Kotiah, Sandy ; He, Bin ; Ghaly, Michael

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are biologically and clinically heterogeneous tumors, most of which overexpress somatostatin receptors (SSTRs). The presence of SSTRs enables staging and allows patient selection for treatment with radiolabeled somatostatin analogs (SSAs), such as DOTATATE. [²²⁵Ac]Ac-DOTATATE is an α-emitting radiopharmaceutical in development for the treatment of patients with SSTR2-expressing solid tumors. α particles have a shorter path length and higher linear energy transfer than do β particles, leading to largely irreparable double-strand DNA breaks and cytotoxicity. ACTION-1 (NCT05477576) is a 2-part, randomized, controlled, open-label, phase 1b/3 trial of [²²⁵Ac]Ac-DOTATATE in patients with SSTR-expressing GEP-NETs whose disease progressed after ¹⁷⁷Lu-labeled SSA therapy. ACTION-1 included a dosimetry substudy to determine the feasibility of obtaining imaging data with ²²⁵Ac. The objectives of the substudy were to estimate radiation absorbed doses of [²²⁵Ac]Ac-DOTATATE in critical organs and tumors. Methods: [²²⁵Ac]Ac-DOTATATE was administered intravenously every 8 wk for 1-4 cycles to adults with grade 1 or 2, well-differentiated, inoperable SSTR2-expressing GEP-NETs that progressed after 2-4 cycles of ¹⁷⁷Lu-lableled SSA. Dosimetry was assessed after cycles 1 and 4 of [²²⁵Ac]Ac-DOTATATE via SPECT/CT of ²²¹Fr (4.8-min half-life), the first daughter and surrogate for ²²⁵Ac and ²¹³Bi (46.6-min half-life, surrogate for later daughters). Absorbed doses and absorbed dose coefficients adjusted for a relative biological effectiveness factor of 5 (ADC_RBE=5) to target tissues and tumors were calculated; tumor doses were estimated by MIRD S-value methodology. Results: Dosimetry data were obtained from 9 of 17 patients in phase 1b, each completing 4 cycles. ²¹³Bi mostly remained with DOTATATE in the tumors; a minor fraction went to the kidneys. The estimated absorbed doses to kidneys and red bone marrow were 22.3 and 1.1 Gy, respectively. The ADC_RBE=5 to selected tumors ranged from 488 to 8775 mGy/MBq across both treatment cycles. The ADC_RBE=5 for most tumors was lower in cycle 4 than in cycle 1; many tumors defined in cycle 1 were unidentifiable in cycle 4. Conclusion: Dosimetry data from ACTION-1 demonstrated the feasibility of image-based dosimetry of ²²⁵Ac through SPECT/CT imaging of ²²¹Fr and ²¹³Bi. The ²¹³Bi daughter mostly remained with DOTATATE in tumors, decaying at the same location as ²²¹Fr. The favorable tumor-to-normal tissue absorbed dose ratio of [²²⁵Ac]Ac-DOTATATE supports its use in patients with SSTR-expressing GEP-NETs.

2026-07-01·European Journal of Nuclear Medicine and Molecular Imaging

Clinical research analysis of [225Ac]Ac-DOTATATE therapy for neuroendocrine neoplasms

Article

作者: Yang, Hongyu ; Liu, Lin ; Hu, Meiling ; Zhang, Yu ; Liu, Ya ; Chen, Yue ; Shen, Bingyan

PURPOSE: To evaluate the efficacy and safety of [225Ac]Ac-DOTATATE therapy in neuroendocrine neoplasms (NENs) with high somatostatin receptor (SSTR) expression. METHODS: Retrospective analysis was conducted in NENs who demonstrated high SSTR expression on [68Ga]Ga-DOTATATE PET/CT and received [225Ac]Ac-DOTATATE therapy. Response was assessed by RECIST 1.1 and PERCIST 1.0 criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Toxicities were graded according to CTCAE v5.0. RESULTS: Thirty-one patients were included. Partial response (PR) and partial molecular response (PMR) were observed in 19.4% and 51.6% of patients, respectively, while stable disease (SD) and stable molecular disease (SMD) were seen in 71.0% and 38.7%, and disease control rate (DCR) of 90.3%. Patients achieving disease control showed significant improvement in Karnofsky Performance Status (increased from 75 to 80, P < 0.001). At a median follow-up of 16 months (range, 5–50 months), the median PFS and OS were not reached. The 6-, 12-, 24-, and 48-month PFS rates were 93.5%, 87.1%, 74.2%, and 44.5%, respectively; the corresponding OS rates were 100%, 93.5%, 77.4%, and 51.6%. Treatment was generally well tolerated. Hematologic toxicities were predominantly G1/2; seven patients experienced G3 events, with no G4 toxicities. Renal and hepatic toxicities were limited to G1/2. The most common adverse events were fatigue and nausea. No treatment-related deaths occurred. CONCLUSION: Our preliminary results suggest that [225Ac]Ac-DOTATATE holds promise as a treatment for SSTR-high NENs, with toxicity that is acceptable and adverse effects that are generally well tolerated.

240

项与锕[225Ac]氧奥曲肽相关的新闻（医药）

2026-10-14

·求实药社

一天暴涨400亿，BMS这两款药什么来头？

10月12日，百时美施贵宝（BMS）宣布，旗下RayzeBio开发的靶向放射性药物RYZ101（225Ac-DOTATATE）在关键Ⅲ期ACTION-1研究的计划中期分析中，以盲态独立中心评审评估的无进展生存期（PFS）为主要终点，达到了具有统计学显著性和临床意义的改善，安全性数据与已知特征一致。同一天，BMS还宣布另一项口服LPA1拮抗剂Admilparant治疗特发性肺纤维化（IPF）的Ⅲ期临床ALPFT-IPF达到FVC主要终点。两项Ⅲ期捷报同日落地，直接反映在二级市场上：消息公布后，BMS股价在盘前早段一度上涨约5.8%，市值一度增加约60亿美元（约合人民币402亿元）。尽管随后股价有所回落，但这一表现仍被视为对BMS管线更新能力与并购逻辑的一次重要验证。在老药王面临专利悬崖的背景下，核药RYZ101和肺纤维化新药Admilparant的积极结果，为公司的未来增长提供了关键支撑，也展现了其在创新领域的持续布局。 01. 里程碑管线来自一笔41亿美元收购 RYZ101并不是BMS从零做起的项目，而是其在2023年底斥资约41亿美元整体收购RayzeBio时拿下的核心资产。这家公司2020年在圣地亚哥成立，创立之初就重点布局当时仍相当冷门的α放射性同位素（225Ac）。RYZ101的分子设计并不复杂：将临床已获验证的生长抑素类似物DOTATATE与225Ac偶联，由配体像“导航”一样找到高表达SSTR2的肿瘤细胞，再由225Ac释放的α粒子对肿瘤细胞实施高LET局部照射。这种偶联思路并不新鲜，真正让RYZ101区别于已上市产品的，是核素本身的选择。目前已商业化的两款放射性配体疗法：诺华的Lutathera和Pluvicto，使用的都是β核素177Lu。β粒子射程长、能量低，对付体积较大的实体瘤有优势，但面对微小转移灶时精度并不宽裕。 225Ac释放的α粒子恰好补上这一短板：线性能量传递高、射程仅几十微米，对已对β核素产生耐药的微小残留病灶，理论上是一种更“硬”的杀伤方式。核素精度之外，RYZ101瞄准的适应证同样经过精准筛选。BMS新闻稿显示，胃肠胰神经内分泌瘤（GEP-NET）是一类相对罕见的肿瘤，美国每年新发病例约1.8万、现患病例不足20万，其中80%–90%的肿瘤组织高表达SSTR2，确诊时多数已经转移。诺华的Lutathera已经把177Lu-DOTATATE推进成这一人群的标准治疗之一，但几乎所有患者最终都会进展；而进展之后的后线选择，高剂量或高频长效生长抑素类似物、依维莫司、舒尼替尼，长期缺乏Ⅲ期随机证据。 ACTION-1正是瞄着这片空白：入组经177Lu类治疗后进展的SSTR阳性晚期GEP-NET患者，随机对照RYZ101与研究者选择的标准治疗。 ACTION-1启动之前，这一组合的安全性已在17例经177Lu治疗后进展的患者中被初步验证：没有出现治疗相关严重不良事件，也没有因不良事件导致的剂量中断。安全性之外，监管端的推进也在同步进行。今年8月，FDA已授予RYZ101治疗GEP-NET的孤儿药资格认定；按BMS的说法，RayzeBio将与FDA沟通后续监管递交路径，详细数据将在未来的学术会议上公布。除GEP-NET外，RYZ101还在更早阶段的试验中探索HR阳性转移性乳腺癌和广泛期小细胞肺癌。不过，站在2026年回头看这笔交易，过程并非一帆风顺。这笔2023年底宣布、2024年2月交割的41亿美元收购，曾被不少投资者质疑“买贵了”；收购完成后不久，又因225Ac上游原料紧张，RayzeBio不得不暂停了另一款PSMA靶向α核药的Ⅲ期新患者入组。两年过去，当PSMA项目仍在等待原料放行时，RYZ101率先在Ⅲ期读出阳性。这份结果，等于给当时那场高溢价并购补上了首个Ⅲ期层面的临床验证：它不仅是BMS肿瘤管线的又一个新分子，更是全球α核素靶向疗法从概念验证走向注册阶段的标志性事件。 02. BMS核药版图与全球赛道的上半场 RYZ101的成功，对BMS而言只是其核药版图浮出水面的第一角。沿RayzeBio留下来的管线往深看，这条225Ac技术平台上已经叠了多个资产：RYZ401是下一代SSTR2靶向分子，2026年4月刚在美国完成首例患者给药；RYZ801靶向GPC3，用于肝细胞癌，并配套了诊断偶联物RYZ811，走的是典型的“诊疗一体化”路径；此外还有针对CA9、肾细胞癌方向的早期项目。 RayzeBio的外部合作同样没有停。2025年6月，RayzeBio与瑞士Philochem达成全球独家许可，引进靶向前列腺酸性磷酸酶（PAP）的诊疗一体化分子OncoACP3，首付款3.5亿美元、里程碑总额最高可达13.5亿美元。在PSMA路线被诺华Pluvicto和大批跟随者挤满之后，PAP提供了一条PSMA阴性前列腺癌的差异化路径。把药物做出来只是上半场，能不能稳定、规模化地把225Ac送到医院，是更难的下半场。 2026年7月，BMS在印第安纳波利斯启用了7.7万平方英尺的新RayzeBio生产基地，已经在生产RYZ101的临床用药；9月，又宣布将在印第安纳州Whitestown追加投资1.73亿美元、新建22.5万平方英尺的生产设施。这种“并购拿管线+自建产能锁供应”的打法，与诺华当年围绕Lutathera、Pluvicto纵向整合同位素的逻辑一脉相承。放到全球坐标系里看，这次Ⅲ期阳性更像是行业共识的一次实证。诺华财报显示，其两款177Lu核药2025年合计销售额已接近28亿美元（Pluvicto约19.94亿美元、Lutathera约8.16亿美元），Lantheus同年总收入约15.46亿美元。多家机构预测，全球放射性配体治疗市场将从2025年的约30亿美元量级，以10%–20%的年复合增速，在2030年代中期成长为百亿美金赛道。在这条主航道上，阿斯利康24亿美元收购Fusion Pharmaceuticals、礼来绑定AdvanCell开发铅-212、拜耳同时押注多家225Ac供应商，跨国巨头的动作几乎清一色指向配体+核素+产能三位一体。中国市场是这一全球产业格局中不可忽视的组成部分。政策端，国家原子能机构等八部委2021年出台的《医用同位素中长期发展规划（2021—2035年）》，明确将医用同位素研发生产纳入国家战略，提出到2025年实现常用医用同位素稳定自主供应，2035年推动医用同位素“走出去”的目标。这一政策为核药产业发展提供了顶层设计和政策支持，加速了核素国产化进程。产业端，中核集团“和福一号”重水堆已实现镥-177等关键核素的规模化量产，中国同辐、纽瑞特等企业也在加速补齐225Ac、177Lu等核素的自主供给能力，逐步打破国外垄断；东诚药业、先通医药、远大医药、纽瑞特等本土玩家在β核素和α核素两条线上同时布局，覆盖从核素生产、药物研发到临床应用的全产业链。阿斯利康宣布在广州黄埔建设225Ac放射性偶联药物生产基地，面向亚太市场，进一步凸显了中国核药市场的吸引力。相比之下，BMS在中国的核药布局仍以同步全球管线节奏为主，目前尚未在国内启动RYZ101的临床注册，后续如若落地，将大概率依托其在肿瘤与免疫领域积累的商业化体系逐步推进。放到整个产业的维度看，这次60亿美元的市值回弹，已超越单款产品获批预期的价值。在RYZ101之前，225Ac靶向疗法的临床价值始终停留在早期数据与理论层面，上游原料供应紧张、规模化生产难度大等问题，一直是压制赛道估值的核心顾虑。如今Ⅲ期临床阳性结果落地，不仅验证了α核素的临床获益，也证明了从核素生产到药物递送的全链路跑通的可能性，为整个行业注入关键信心。但这只是核药新周期的上半场节点，下半场的竞争将围绕核素供应链的稳定可控、多适应症管线的临床拓展、生产成本的下探以及全球商业化能力的比拼深入展开，这条百亿赛道的格局，才刚刚拉开序幕。联系我们 AntibodyChina 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

2026-10-14

·药时代

BMS两项III期临床成功，怎么股价跌了

BMS同天甩出两项 III 期临床成功，股价反而跌了2.6%。按理说这是双重利好。可市场根本不买账，开盘冲高后迅速回落，最终收跌。先看肺纤维化新药Admilparant。低剂量达标了，高剂量却没显出统计学差异。这在药物开发中是一个异常信号，更高剂量往往意味着更强的靶点抑制，若低剂量有效，高剂量理应表现不劣。此外，BMS尚未公布效应量、置信区间、P值或关键次要终点等数据，仅表示全部研究结果支持admilparant作为同类首创疗法的潜力。投资者被迫在信息真空中定价。让华尔街神经紧绷的，还有安全性问题。此前，BMS在欧洲修改了试验安全监测方案，随后在ALOFT项目中，报告了一例急性肝损伤导致的多器官衰竭死亡事件。公司确认该死亡病例出现在120mg剂量组，裁定委员会判定与研究治疗不太可能相关，但这一事件与高剂量组的统计学失败叠加，客观上削弱了120mg剂量的可信度。BMO分析师Evan Seigerman的评论切中要害：此次结果验证了LPA1机制，但数据不太可能被视为完全干净。再看肿瘤药RYZ101。中期分析确实改善了无进展生存期。但总生存期数据还没出来。此外，对照组又较为复杂。ACTION-1对照的是研究者选择的标准治疗，而非单一药物，这增强了外部效度，却也让疗效对比的归因更为复杂，投资者难以据此建立清晰的收入模型。再者，供应链存在瓶颈。锕-225是稀缺同位素，放射性药物的生产、配送和给药需要专门基础设施，商业化放量的可行性仍需观察。说白了，资本市场现在只认确定性。BMS的老药Eliquis与Opdivo马上要面临专利悬崖。投资者真正追问的是：这些新资产能不能及时补上缺口？光有临床成功，托不住股价。 #BMS #临床试验 #肺纤维化 #放射性药物 #专利悬崖

2026-10-14

·BioSpace

J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart > Watch on YouTube Third quarter earnings are upon us, as Johnson & Johnson kicked off this spooky season on Tuesday with a report “in line” with analyst expectations. While the earnings beat was supported by the company’s innovative medicines division, J&J’s stock slipped about 4% on the underperformance of its medtech unit. Meanwhile, Bristol Myers Squibb, which reports Q3 earnings Oct. 29, has had a “mixed” week. The company’s lung disease asset scored a low-dose win in a Phase 3 idiopathic pulmonary fibrosis trial but failed to significantly improve exhalation capacity at a higher dose. BMS enjoyed a more decisive Phase 3 victory with RYZ-101 as the asset, picked up in the company’s $4.1 billion acquisition of RayzeBio, improved progression-free survival for patients with a rare type of gastrointestinal tract cancer. This all comes as BMO Capital Markets questions the company’s plan to manage the upcoming loss of exclusivity for Opdivo and Eliquis. One company analysts will be watching closely when smaller biotechs begin to report Q3 earnings is Revolution Medicines, whose “miracle” pancreatic cancer drug Rasonque won FDA approval in August. While the drug’s launch is widely expected to set records, RevMed dipped last week after the FDA released review documents showing that Rasonque appeared to work better in some patient subgroups than others. Speaking of smaller biotechs, it’s been a rough month for Adecto Pharmaceuticals and Aviceda Therapeutics, both of which are exiting the scene . And last week, news broke that Caribou Biosciences —co-founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna—has discontinued its entire clinical-stage pipeline and will part with 87 employees—the majority of its staff—by the end of the year. Finally, enjoy our thoughts on the Major League Baseball playoffs and our favorite all-time Halloween movies.

临床3期并购临床结果上市批准

100 项与锕[225Ac]氧奥曲肽相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类癌	临床3期	美国	Rayzebio, Inc.	2022-03-24
类癌	临床3期	比利时	Rayzebio, Inc.	2022-03-24
类癌	临床3期	巴西	Rayzebio, Inc.	2022-03-24
类癌	临床3期	加拿大	Rayzebio, Inc.	2022-03-24
类癌	临床3期	法国	Rayzebio, Inc.	2022-03-24
类癌	临床3期	荷兰	Rayzebio, Inc.	2022-03-24
类癌	临床3期	韩国	Rayzebio, Inc.	2022-03-24
类癌	临床3期	西班牙	Rayzebio, Inc.	2022-03-24
功能性内分泌肿瘤	临床3期	美国	Rayzebio, Inc.	2022-03-24
功能性内分泌肿瘤	临床3期	比利时	Rayzebio, Inc.	2022-03-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05477576 (ACTION-1, ASCO_GI2025)	临床1期	类癌 \| 功能性内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤 SSTR2+	17	RYZ101 120 kBq/kg	觸製鬱範繭窪餘糧簾鹽(衊憲艱醖網繭窪夢醖範) = There was one grade 5 TEAE of hepatic failure that was deemed unrelated to the study drug 鏇範觸憲廠積遞齋壓廠 (餘鑰獵廠憲積選醖餘齋 ) 更多	积极	2025-01-23
NCT05477576 (ACTION-1, ASCO_GI2025)	临床1期	类癌 \| 功能性内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤 SSTR2+	17	RYZ101 90 kBq/kg		积极	2025-01-23
NCT05595460 (WCLC2024) 人工标引	临床1期	广泛期小细胞肺癌	10	RYZ101 carboplatinTATetoposideatezolizumab	餘製糧鹹顧壓齋構獵窪(築醖觸繭鹹淵鬱築襯網) = G1 decreased appetite, G2 dehydration, G1 diarrhea, G1 fatigue, G2 influenza-like illness, G2 nausea, G2 neutrophil count decrease, G1 vomiting 蓋鹹鹽顧廠製簾壓膚鑰 (遞衊襯壓築築鹹艱鬱觸 ) 更多	积极	2024-09-08
NCT05477576 (SNMMI2024)	临床3期	胃肠胰神经内分泌肿瘤	-	RYZ101 120 kBq/kg	餘淵淵願廠構願觸積獵(醖鬱網獵積鏇鬱獵簾遞) = 52.9% 鹽齋築蓋鹽鹽簾願鹽簾 (顧餘艱範廠餘獵選鹽衊 ) 更多	-	2024-06-09
NCT05477576 (ACTION-1, ASCO2024) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR2	17	RYZ101 120 kBq/kg	鏇廠膚鹽憲膚艱衊選鹹(鹹選醖鑰鏇鏇衊繭窪鹹) = 積蓋鑰鹹鬱夢衊網艱餘齋餘夢選醖網積製鹹糧 (鑰築襯齋網顧衊網願範 ) 更多	积极	2024-05-24
NCT05477576 (ACTION-1, ESMO 12023 \| ESMO 22023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR positive	17	RYZ101 120kBq/kg	鬱獵鑰襯積襯窪獵膚獵(簾夢醖憲壓窪網廠築齋) = 觸簾憲襯蓋範淵蓋鹹範窪築網窪鏇鹽襯鹽鹽網 (襯構淵淵廠齋齋簾積構 ) 更多	积极	2023-10-22
NCT05477576 (ACTION-1, ASCO 12023 \| ASCO 22023) 人工标引	临床1期	SSTR2阳性胃肠胰神经内分泌肿瘤 SSTR2 Expression	9	RYZ101	夢範獵憲鬱構簾觸積繭(襯積鹹網餘遞鬱衊壓網) = 襯選構夢獵遞襯鹹餘憲遞鬱繭鏇鬱齋範醖範蓋 (蓋觸衊壓繭壓製夢選壓 ) 更多	积极	2023-05-31
SNMMI2022	N/A	胃肠胰神经内分泌肿瘤	-	225Ac-DOTATATE TAT	糧齋襯夢網築鹹憲醖遞(構鹹積蓋顧遞鏇齋鏇獵) = Malignant ascites was noted in 14, resulting in 11 deaths 觸選醖積築選蓋遞窪鹽 (衊繭鏇淵艱獵鑰淵鏇廠 ) 更多	-	2022-08-08
SNMMI2022	N/A	胃肠胰神经内分泌肿瘤	-	177Lu-DOTATATE		-	2022-08-08
SNMMI2021	N/A	胃肠胰神经内分泌肿瘤	-	225Ac-DOTATATE	鑰鏇膚簾積衊獵夢艱糧(獵鑰構襯鑰鑰製鬱鏇鏇) = No grade 3 renal or hepatotoxicities were observed. No other unexpected longer-term adverse events were observed with 225Ac-DOTATATE therapy 衊構選範觸衊鹹醖襯齋 (憲糧選襯壓廠齋糧齋艱 ) 更多	-	2021-05-18